Loading…
Cytokinetics, Incorporated is projected to rise to $99.74 by 2027, a +24% move from its current price of $80.42. CYTK is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/31/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Aug 1 | $79.11 | $80.43 | $81.78 | +0.02% |
| Aug 2 | $78.58 | $80.45 | $82.36 | +0.03% |
| Aug 3 | $78.18 | $80.46 | $82.81 | +0.05% |
| Aug 4 | $77.85 | $80.47 | $83.19 | +0.07% |
| Aug 5 | $77.56 | $80.49 | $83.53 | +0.09% |
| Aug 6 | $77.30 | $80.50 | $83.84 | +0.10% |
| Aug 7 | $77.06 | $80.52 | $84.13 | +0.12% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $77.06 | $80.52 | $84.13 | +0.12% |
| Week 2 | $75.76 | $80.61 | $85.78 | +0.24% |
| Week 3 | $74.80 | $80.71 | $87.08 | +0.36% |
| Week 4 | $74.01 | $80.80 | $88.22 | +0.48% |
| Week 5 | $73.34 | $80.90 | $89.25 | +0.60% |
| Week 6 | $72.74 | $81.00 | $90.19 | +0.72% |
| Week 7 | $72.20 | $81.09 | $91.08 | +0.84% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Cytokinetics, Incorporated is a healthcare company focused on discovering, developing, and commercializing novel muscle activators and muscle inhibitors as potential treatments for debilitating diseases in the United States.
The company markets MYQORZO, a novel, oral, and small molecule cardiac myosin inhibitor for the treatment of symptomatic oHCM. It also develops Aficamten, a novel, oral, and small molecule cardiac myosin inhibitor for the treatment of HCM; and omecamtiv mecarbil, a potential treatment across the continuum of care in heart failure with severely reduced ejection fraction. In addition, the company is involved in developing Ulacamten, a novel, selective, oral, and small molecule cardiac myosin inhibitor designed to reduce the hypercontractility associated with heart failure with preserved ejection fraction in Phase 1 clinical trials; and CK-089, a fast skeletal muscle troponin activator in Phase 1 clinical trials.
Cytokinetics, Incorporated was incorporated in 1997 and is headquartered in South San Francisco, California.
Cytokinetics, Incorporated (CYTK) is a healthcare stock currently trading at $80.36, with a market capitalization of $10.91B and a rank of 866.
The asset sits in the Healthcare sector and has a current price of $80.36 with a substantial market position at $10.91B market cap and a ranking of 866. The year-by-year forecast suggests a rising price trajectory through 2050, with the average price climbing from the 2026 level toward markedly higher levels by 2050.
A major floor 25.9% below — a decisive break under it would weaken the trend.
Price is testing support right now (2.9% away) — a key level to hold.
The nearest ceiling, 8.5% above — a clean break opens room to run.
A major ceiling 13.3% above — clearing it would confirm fresh momentum.
Key CYTK support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of CYTK market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $79.92 | Buy | $80.01 | Buy |
| MA 10 | $80.41 | Buy | $80.55 | Sell |
| MA 20 | $82.24 | Sell | $80.84 | Sell |
| MA 50 | $78.57 | Buy | $78.44 | Buy |
| MA 100 | $72.40 | Buy | $74.14 | Buy |
| MA 200 | $67.84 | Buy | $67.74 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 49.78 | Neutral |
| Stoch RSI (14) | 53.53 | Neutral |
| CCI (20) | -59.31 | Neutral |
| Williams %R (14) | -52.01 | Info |
| MACD (12,26,9) | -0.64 | Sell |
| ROC (12) | -1.84 | Sell |
| Bollinger %B (20,2) | 0.31 | Neutral |
| Stochastic %K (14) | 47.99 | Neutral |
| TRIX (15) | 0.16 | Buy |
| Awesome (5,34) | -0.92 | Sell |
| Ultimate (7,14,28) | 43.54 | Neutral |
| Momentum (10) | 0.06 | Buy |
| Aroon Osc (25) | -84.00 | Sell |
| Hull MA (9) | 79.03 | Buy |
| ADX (14) | 14.01 | Neutral |
| ATR (14) | 1.21 | Info |
The 30-day technical picture is bullish overall, with RSI14 at 50.
The moving averages show SMA50 at $77.67 and SMA200 at $66.72, providing a near-term bullish bias as price sits above the longer-term trend. Support is indicated at $67.07 and resistance at $87.26, framing a constructive path higher from here.
The 30-day range runs from a low of $70.78 to a high of $91.24, underscoring a positive but varied near-term trading environment.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $59.58 | $80.42 | $106.08 | 0% | Neutral | |
| $81.78 | $99.74 | $127.11 | +24% | Bullish | |
| $94.94 | $117.99 | $154.50 | +47% | Bullish | |
| $97.79 | $123.43 | $165.10 | +53% | Bullish | |
| $104.52 | $133.72 | $182.11 | +66% | Bullish | |
| $130.64 | $169.18 | $234.07 | +110% | Bullish | |
| $149.64 | $195.99 | $275.04 | +144% | Bullish | |
| $164.85 | $218.19 | $310.18 | +171% | Bullish | |
| $177.82 | $237.70 | $341.97 | +196% | Bullish | |
| $178.71 | $241.16 | $350.83 | +200% | Bullish | |
| $289.92 | $408.09 | $622.21 | +407% | Bullish | |
| $570.23 | $860.88 | $1,407.18 | +970% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $59.58 | $80.42 | $93.71 | +0.00% |
| August 2026 | $69.79 | $81.38 | $96.70 | +1.19% |
| September 2026 | $69.65 | $81.68 | $97.97 | +0.37% |
| October 2026 | $71.70 | $84.47 | $102.08 | +3.42% |
| November 2026 | $73.30 | $86.68 | $105.37 | +2.61% |
| December 2026 | $73.14 | $86.78 | $106.08 | +0.12% |
Click any year to see its month-by-month CYTK forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
Cytokinetics, Incorporated's 2026 outlook centres on $80.42, within a $59.58 to $106.08 range. That marks a 0% change versus current levels. Price action looks broadly range-bound.
By 2027, CYTK could reach as high as $127.11, with a base case around $99.74 and support toward $81.78 — roughly +24% from $80.42. Buyers look set to stay in control over this stretch.
Expect CYTK to range from $94.94 to $154.50 through 2028. The $117.99 average target implies a +47% move from current prices. That is up +18% on the projected 2027 average. Momentum favours further upside here.
The CYTK price prediction for 2029 points to an average of $123.43 (low $97.79, high $165.10) — a potential gain of +53% on today's $80.42. Buyers look set to stay in control over this stretch.
In 2030, CYTK is projected to trade between $104.52 and $182.11, averaging $133.72 — a potential gain of +66% from today's $80.42. That is up +8% on the projected 2029 average. Momentum favours further upside here.
Cytokinetics, Incorporated's 2031 outlook centres on $169.18, within a $130.64 to $234.07 range. That is up +27% on the projected 2030 average. That marks a +110% change versus current levels. Buyers look set to stay in control over this stretch.
By 2032, CYTK could reach as high as $275.04, with a base case around $195.99 and support toward $149.64 — roughly +144% from $80.42. Momentum favours further upside here.
Expect CYTK to range from $164.85 to $310.18 through 2033. The $218.19 average target implies a +171% move from current prices. That is up +11% on the projected 2032 average. Buyers look set to stay in control over this stretch.
The CYTK price prediction for 2034 points to an average of $237.70 (low $177.82, high $341.97) — a potential gain of +196% on today's $80.42. Momentum favours further upside here.
In 2035, CYTK is projected to trade between $178.71 and $350.83, averaging $241.16 — a potential gain of +200% from today's $80.42. That is up +1% on the projected 2034 average. Buyers look set to stay in control over this stretch.
Cytokinetics, Incorporated's 2040 outlook centres on $408.09, within a $289.92 to $622.21 range. That is up +69% on the projected 2035 average. That marks a +407% change versus current levels. Momentum favours further upside here.
By 2050, CYTK could reach as high as $1,407.18, with a base case around $860.88 and support toward $570.23 — roughly +970% from $80.42. Buyers look set to stay in control over this stretch.
Investing $1,000 in CYTK today (≈ 12.434718 CYTK) could be worth
$10,704.85
+$9,704.85 (+970%) by 2050 · US Dollar
Based on the average projected CYTK price of $860.88 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in CYTKwould be worth at today's price.
$1,000 invested in CYTK on Jul 30, 2025 (≈ 27.63958 CYTK) would be worth
$2,222.77
+$1,222.77 (+122.3%) today · 2.22× · US Dollar
Based on a CYTK entry price of $36.18 vs. today's $80.42.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $81.92 | $981.69 | -1.8% |
| 1 month ago | $85.19 | $944.01 | -5.6% |
| 3 months ago | $63.35 | $1,269.46 | +26.9% |
| 6 months ago | $63.19 | $1,272.67 | +27.3% |
| 1 year ago | $36.18 | $2,222.77 | +122.3% |
| All time (5.0y) ago | $28.77 | $2,795.27 | +179.5% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our CYTK forecast.
Our base-case forecast reaches $160.00 around 2031.
Implied market cap at $160.00: $21.72B
The multi-year forecast shows the average price rising significantly from 2026 onward, with 2026 min $59.58, avg $80.36, max $107.15 and ROI 0 (sentiment NEUTRAL).
In 2027, the forecast produces min $83.72, avg $102.33, max $130.83 with ROI 27.3 and sentiment BULLISH, followed by stronger upside in 2028 (min $95.50, avg $118.98, max $156.34; ROI 48.1; BULLISH) and 2029 (min $99.13, avg $125.46, max $168.44; ROI 56.1; BULLISH).
By 2030, the forecast shows min $108.54, avg $139.28, max $190.43 with ROI 73.3 and sentiment BULLISH, continuing to 2031–2035 with substantial gains (2031 min $135.18, avg $175.64, max $244.02; ROI 118.6; 2032 min $154.67, avg $203.29, max $286.55; ROI 153; 2033 min $171.60, avg $227.98, max $325.58; ROI 183.7; 2034 min $184.17, avg $247.18, max $357.31; ROI 207.6; 2035 min $186.04, avg $252.12, max $368.58; ROI 213.7).
The forecast extends to 2040 with min $303.00, avg $428.77, max $657.43; ROI 433.6 and sentiment BULLISH, and to 2050 with min $607.52, avg $923.85, max $1,520.19; ROI 1049.6 and sentiment BULLISH. These figures illustrate a path of continued upside potential, tempered by the usual investment uncertainties and risks inherent to future projections.
Tap a question to reveal the answer.
In 2030, the forecast shows an average price of $139.28, with a min of $108.54 and a max of $190.43; ROI 73.3; sentiment BULLISH.
The 2026 forecast shows an average price of $80.36 with ROI 0 and sentiment NEUTRAL, then from 2027 onward the outlook is BULLISH with rising averages toward 2030 and beyond. These are estimates, not guarantees.
Yes. The forecast indicates prices exceeding $200 in 2032 (avg $203.29; max $286.55) and continuing higher in subsequent years (2033 avg $227.98; max $325.58).
The 30-day range is $70.78 to $91.24, with a 50-day SMA of $77.67 and a 200-day SMA of $66.72. Support is at $67.07 and resistance at $87.26.
For 2040, the min is $303.00, avg $428.77, max $657.43; ROI 433.6; sentiment BULLISH.
Cytokinetics, Incorporated Community Discussion
0Share your Cytokinetics, Incorporated price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.